82
Participants
Start Date
February 28, 2001
Primary Completion Date
January 31, 2004
Study Completion Date
January 31, 2004
Fabrazyme (agalsidase beta)
1mg/kg Fabrazyme (agalsidase beta) every 2 weeks
Placebo
1 mg/kg placebo intravenously every 2 weeks
Sopron Megyei Jogu Varos Erzsebet Korhaz, Sopron
Mount Sinai School of Medicine, New York
Children's Hospital, Buffalo
University of Rochester School of Medicine, Rochester
University of Pittsburgh, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Duke University Medical Center, Durham
Emory University School of Medicine, Atlanta
Oncology Hematology Association, Coral Springs
University of Alabama at Birmingham, Birmingham
Children's Hospital Medical Center, Cincinnati
Gene Therapy Center - Dept. of Pediatrics and Institute of Human Genetics, Minneapolis
Children's Memorial Hospital, Chicago
University of Kansas Medical Center, Kansas City
Baylor College of Medicine, Houston
Cedars-Sinai Medical Center, Los Angeles
University of San Francisco, San Francisco
University of Washington School of Medicine, Seattle
University of Connecticut Health Partners, Farmington
Massachusetts General Hospital, Boston
Queen Elizabeth II Health Center, Halifax
North York General Hospital, Toronto
Hopital du Sacre-Coeur de Montreal, Montreal
University Hospital, Prague
Klinika Chorob Metabolicznych Instytut, Warsaw
Hope Hospital, Manchester
Genzyme, a Sanofi Company
INDUSTRY